Treatment of Helicobacter pylori infection in Korea: A systematic review and meta-analysis

Journal of Korean Medical Science

Volumn 30, Issue 8, 2015, Pages 1001-1009

  Lee, Sang Wook ^a   Kim, Hyun Jung ^b   Kim, Jae Gyu ^a  

^a Chung Ang University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Disease Eradication; Helicobacter pylori; Review; Systematic; Treatment

Indexed keywords

ANTIINFECTIVE AGENT;

CLASSIFICATION; CLINICAL PRACTICE; DRUG EFFECTS; EVIDENCE BASED MEDICINE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; MALE; META ANALYSIS; MICROBIOLOGY; PREVALENCE; RISK ASSESSMENT; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; REPUBLIC OF KOREA; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84951750204     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2015.30.8.1001     Document Type: Review

References (36)

1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, et al.; European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
2. Chung JW, Lee GH, Han JH, Jeong JY, Choi KS, Kim DH, Jung KW, Choi KD, Song HJ, Jung HY, et al. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011; 58: 246-50.
3. Kim JS, Ji JS, Choi H, Kim JH. Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2014; 38: 118-25.
4. Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, Oh DH, Jang DK, Chung JW. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013; 28: 1801-9.
5. Kim JS, Kim BW, Ham JH, Park HW, Kim YK, Lee MY, Ji JS, Lee BI, Choi H. Sequential therapy for Helicobacter pylori infection in Korea: systematic review and meta-analysis. Gut Liver 2013; 7: 546-51.
6. Chung JW, Ha M, Yun SC, Kim JH, Lee JJ, Kim YJ, Kim KO, Kwon KA, Park DK, Lee DH. Meta-analysis: sequential therapy is superior to conventional therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2013; 62: 267-71.
7. Jung HS, Shim KN, Baik SJ, Na YJ, Kang MJ, Jung JM, Ha CY, Jung SA, Yoo K. Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication. Korean J Gastroenterol 2008; 51: 285-90.
8. Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009; 14: 77-85.
9. Chung JW, Jung YK, Kim YJ, Kwon KA, Kim JH, Lee JJ, Lee SM, Hahm KB, Lee SM, Jeong JY, et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012; 27: 1675-80.
10. Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18: 2377-82.
11. Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther 2012; 35: 56-65.
12. Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34: 1098-105.
13. Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, Kim JW, Hwang JH, Park YS, Lee SH, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012; 27: 504-9.
14. Choi WH, Park DI, Oh SJ, Baek YH, Hong CH, Hong EJ, Song MJ, Park SK, Park JH, Kim HJ, et al. Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008; 51: 280-4.
15. Kim SY, Lee SW, Hyun JJ, Jung SW, Koo JS, Yim HJ, Park JJ, Chun HJ, Choi JH. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013; 47: 21-4.
16. Lim JH, Lee DH, Choi C, Lee ST, Kim N, Park YS, Shin CM, Cho HJ. Two weeks sequential and concomitant therapy for Helicobacter pylori infection and factors associated with eradication: a prospective randomized trial. Journal of Gastroenterology and Hepatology; 111 River ST, Hoboken 07030-5774. NJ USA: Wiley-Balckwell, 2012, p.60.
17. Jang HJ, Choi MH, Kim YS, Seo YA, Baik KH, Baik IH, Eun CS, Kim JB, Kae SH, Kim DJ, et al. Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2005; 46: 368-72.
18. Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, Oak JH, Jung SH. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011; 26: 785-90.
19. Cho YJ, Chun HJ, Kim ST, Koh DW, Park JH, Park DK, Park CH, Lee SJ, Jeen YT, Lee HS, et al. Analysis of eradication rate of Helicobacter pylori according to treatment duration by using 13C-urea breath test comparison of OAC 7, 10 or 14 days regimen. Korean J Gastrointest Endosc 2001; 23: 207-12.
20. Kim BG, Lee DH, Ye BD, Lee KH, Kim BW, Kim SG, Kim SW, Kim SK, Kim JJ, Kim HY, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: Neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31-5.
21. Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006; 11: 46-51.
22. Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS. Second-line treatment for Helicobacter pylori infection: 10-Day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 2007; 12: 623-8.
23. Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: Effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45.
24. Yoon JH, Baik GH, Kim YS, Suk KT, Shin WG, Kim KH, Kim KO, Park CH, Baik IH, Jang HJ, et al. Comparison of the eradication rate between 1-and 2-week bismuth-containing quadruple rescue therapies for Helicobacter pylori eradication. Gut Liver 2012; 6: 434-9.
25. Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, Song HJ, Lee GH, Kim JH. Second-line Helicobacter pylori eradication: a randomized com parison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289-94.
26. Jeong MH, Chung JW, Lee SJ, Ha M, Jeong SH, Na S, Na BS, Park SK, Kim YJ, Kwon KA, et al. Comparison of rifabutin-and levofloxacin-based third-line rescue therapies for Helicobacter pylori. Korean J Gastroenterol 2012; 59: 401-6.
27. Lee SK, Lee SW, Park JY, Kwon BS, Kim SY, Hyun JJ, Kim JH, Jung SW, Koo JS, Yim HJ, et al. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter 2011; 16: 410-4.
28. Park HK, Lee DH, Suh S, Seo PJ, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, et al. Dual therapy trial using esomeprazole and amoxicillin as third-line rescue therapy for Helicobacter pylori infection. Clin Endosc 2011; 44: 33-7.
29. Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, Kwon CI, Ko KH, Hwang SG, Park PW, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver 2012; 6: 452-6.
30. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung ISCNKCH, Upper Gastrointestinal Research CNKAoG. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009; 54: 269-78.
31. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
32. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
33. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
34. Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79-88.
35. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006; 28: 6-13.
36. Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroenterol 2014; 49: 528-38.